

## **How closely is COVID-19 related to HCoV, SARS, and MERS? : Clinical comparison of coronavirus infections and identification of risk factors influencing the COVID-19 severity using common data model (CDM)**

Yeon Hee Kim<sup>1</sup>, YeHee Ko<sup>1</sup>, Soo Young Kim<sup>1</sup>, Kwangsoo Kim<sup>2</sup>

1. Biomedical Research Institute, Seoul National University Hospital
2. Transdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital

## Background

COVID-19, a global pandemic that has caused more than a million deaths and nearly 50 million cases since its outbreak<sup>1</sup>, is a novel respiratory viral disease caused by the SARS-CoV-2 virus that was first discovered in Wuhan, China, in December of 2019<sup>2</sup>. Coronaviruses are the RNA viruses that are commonly present in bats and belong to the family *Coronaviridae*. The family comprises four genera, *Alphacoronavirus*, *Betacoronavirus*, *Gammacoronavirus* and *Deltacoronavirus*, of which the two, *Alphacoronavirus* and *Betacoronavirus* are known to cause respiratory infections in humans. In addition to the COVID-19, there are six other human coronaviruses that have been previously reported since the 1960s, including HCoV229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV-1, and MERS-CoV. While the HCoV strains cause mild upper respiratory diseases, the zoonotic strains including the SARS-CoV-1, MERS-CoV, and SARS-CoV-2 cause severe respiratory symptoms and complications with high mortality rates<sup>3-6</sup>. With the continuum of emergency outbreaks from coronavirus, a comparative assessment of the clinical traits between the infections and a stratification of common clinical variables by severity of the novel COVID-19 can be, therefore, useful in determining the specific at-risk population of each disease, risk factors of infection and severity, and degree of resemblance between the coronaviruses, in order to establish a comprehensive set of data. Thus, in this study, we aim to perform, using the real-world data of Seoul National University Hospital, a clinical characterization of the infected South Korean patients of HCoV strains, SARS-CoV, MERS-CoV, and SARS-CoV-2, and observe whether any common or distinct trait observed between the diseases may significantly influence the prognosis of the COVID-19 patients.

## Methods

### I. Data source

We designed a retrospective cohort observational study using Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) based in Seoul National University Hospital located in Seoul, South Korea. CDM is the database that houses EMR records transformed into the common format to be used by the multiple institutions for research purposes. It is the global data network shared by 19 different countries with more than half a billion patient records altogether. The platform provides deidentified patient records of demographics, diagnosis, hospital admission, provider, prescription, and laboratory values, and vital statuses<sup>7</sup>. Due to the privacy policy, there was no patient mortality information in our database. There was no patient or public involvement in this study. The study was approved by the Institutional Review Board (Seoul, South Korea).

### II. Study Cohort

The follow-up period was from October 15<sup>th</sup> of 2004 to July 31<sup>st</sup> of 2020. Without any restriction on age and gender, we collected the records of symptoms, comorbidities, and laboratory test results of patients who were diagnosed with HCoV229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1 (HCoVs), SARS-CoV, MERS-CoV, and SARS-CoV-2 infections using International Classification of Diseases, Tenth Revision (ICD-10)<sup>8</sup>. The index date of virus infection was determined by the first visit to the hospital. We divided the COVID-19 patients by their disease severity based on the published criteria from the World Health Organization (WHO)<sup>9</sup>. Among the COVID-19 confirmed patients, those who

experienced mild cold-like symptoms with no existing pneumonia were classified as mild, whereas the patients who reported any clinical presentation of pneumonia only or with oxygen saturation (SpO<sub>2</sub>) under 90% were classified as non-mild. Laboratory test results were divided into low, normal, and high levels with a reference to published ranges by Seoul Clinical Laboratories<sup>10</sup> (Appendix 1).

### III. Statistical analysis

There are total three statistical analyses in this study. First, we conducted a comparative clinical characterization of four disease groups with COVID-19 group as a reference. Continuous variables were expressed by the mean values with  $\pm$  standard deviations (SD) with the appropriate units whereas categorical variables were represented by frequency and percentage (%). The Student's t-test, Scheffe post-hoc test, Games-howell post-hoc test, one-way Anova test, and Welch's test were used to compare continuous variables, and the  $\chi^2$  test or Fisher's exact test were used for the categorical variables<sup>11-13</sup>. With the same set of variables, listed analyses above were performed to compare between the mild and non-mild COVID-19 groups. To perform a univariate logistic regression<sup>14-15</sup> to explore the extent of influence by risk factors on severity of COVID-19, we set two criteria for a variable selection. First, we considered statistical similarity between the variables of disease groups to reflect clinical resemblance between the patients. Second, among the variables that showed such similarity, we selected the ones with p-values less than 0.05 in severity analyses. The regression model was adjusted to age and gender. We excluded any variable that had null or sparse patient records. All statistical analyses were carried using R version 3.6.2.

## Results

### I. Comparative analyses between the coronavirus infections

#### *Demographic and clinical characteristics*

For the study, we collected the records of 2840 COVID-19 patients, 67 MERS patients, 43 SARS patients, and 87 other HCoV positive patients. Table 1 shows the summary of clinical characteristics of the COVID-19, MERS, SARS, and HCoV patients. Among the COVID-19 patients, the mean age was  $49.5 \pm 25.9$  and 1457 (51.3%) were males. Among the MERS patients, the mean age was  $33.0 \pm 21.7$  and 35 (52.2%) were males whereas among the SARS and HCoV patients, the mean age of patients was  $45.6 \pm 30.9$  and  $10.6 \pm 17.9$ , and 31 (72.1%) and 46 (52.9%) were males, respectively. From the comparison, COVID-19 group was significantly more likely to experience cancer (29.5% vs. 3.0%,  $p < 0.001$ ) and gastrointestinal diseases (14.4% vs. 1.5%,  $p < 0.01$ ) compared to the MERS group, whereas a higher proportion of SARS patients reported cerebrovascular (11.6% vs. 2.6%,  $p < 0.001$ ), hepatic disease (11.6% vs. 4.6%,  $p < 0.05$ ), renal disease (16.3% vs. 6.4%,  $p < 0.01$ ) than the COVID-19 group. In symptom presentation, MERS and HCoV patients experienced fever (79.1% vs. 33.0%,  $p < 0.001$  and 56.3% vs. 33.0%,  $p < 0.001$ , respectively) and upper respiratory infections (28.4% vs. 0.8%,  $p < 0.001$  and 34.5% vs. 0.8%,  $p < 0.001$ ) more frequently than the COVID-19 patients.

Characteristic	COVID-19 (n=2840)	MERS (n=67)	p-val	SARS (n=43)	p-val	HCoV (n=87)	p-val
<b>Age (years)</b>							
Total	49•48 ± 25•94	33•04 ± 21•74	<0•0001	45•64 ± 30•93	0•422	10•59 ± 17•89	<0•0001
0-19	434 (15•28)	19 (28•35)	0•0035	13 (30•23)	0•0072	72 (82•76)	<0•0001
20-39	563 (19•82)	21 (31•34)	0•020	3 (6•98)	0•033	8 (9•20)	0•014
40-59	561 (19•75)	19 (28•35)	0•082	8 (18•60)	0•851	2 (2•30)	<0•0001
60-79	941 (33•13)	7 (10•45)	<0•001	14 (32•56)	0•937	5 (5•74)	<0•0001
80+	341 (12•00)	1 (1•49)	0•003	5 (11•63)	0•939	0 (0•00)	NA
<b>Gender</b>							
Male	1457 (51•30)	35 (52•23)	0•879	31 (72•09)	0•0068	46 (52•87)	0•773
<b>Comorbidities</b>							
Total	1376 (48•45)	7 (10•45)	<0•0001	26 (60•47)	0•118	31 (35•63)	0•018
Diabetes	124 (4•36)	1 (1•49)	0•366	3 (6•98)	0•436	1 (1•15)	0•182
Cardiovascular disease	214 (7•53)	0 (0•00)	NA	6 (13•95)	0•116	12 (13•79)	0•031
Cerebrovascular disease	73 (2•57)	0 (0•00)	NA	5 (11•63)	0•00028	2 (2•30)	1•000
Malignancy	837 (29•47)	2 (2•98)	<0•0001	8 (18•60)	0•120	9 (10•34)	0•00011
Hepatic disease	132 (4•65)	0 (0•00)	NA	5 (11•63)	0•033	1 (1•15)	0•185
Gastrointestinal disease	410 (14•44)	1 (1•49)	0•00061	9 (20•93)	0•230	6 (6•90)	0•047
Renal disease	183 (6•44)	4 (5•97)	1•000	7 (16•27)	0•099	3 (3•45)	0•259
Thyroidal disease	30 (1•06)	1(1•49)	0•516	1 (2•32)	0•374	2 (2•30)	0•246
Musculoskeletal disease	63 (2•22)	0 (0•00)	NA	1 (2•32)	0•622	8 (9•20)	<0•0001
<b>Symptoms</b>							
Total	1333 (46•94)	63 (94•03)	<0•0001	17 (39•53)	0•334	67 (77•01)	<0•0001
Fever	939 (33•06)	53 (79•10)	<0•0001	9 (20•9)	0•093	49 (56•32)	<0•0001
Cough	102 (3•59)	8 (11•94)	0•00040	3 (6•98)	0•205	6 (6•90)	0•107
Dyspnea	128 (4•51)	2 (2•99)	0•768	6 (13•95)	0•0035	5 (5•75)	0•584
Chest pain	63 (2•22)	0 (0•00)	NA	1 (2•32)	0•622	0 (0•00)	NA
Sore throat	51 (1•80)	3 (4•48)	0•127	0 (0•00)	NA	1 (1•15)	1•000
Gastrointestinal symptoms	193 (6•80)	1 (1•49)	0•129	2 (4•65)	1•000	6 (6•90)	0•971
Upper respiratory infection	23 (0•81)	19 (28•36)	<0•0001	2 (4•65)	0•052	30 (34•48)	<0•0001

Table 1. Summary of clinical characteristics between the HCoVs, SARS, MERS, COVID-19 groups. Data are presented as the mean ± standard deviation for the continuous variables, otherwise the number of patients and percentage

### Laboratory findings

Laboratory findings of each disease group are summarized in Table 2. Overall, COVID-19 patients showed increases in the level of creatinine and prothrombin time, and together with the SARS groups, experienced the elevated levels of alkaline phosphatase, total bilirubin, aminotransferases, and blood urea nitrogen. MERS group reported a high level of creatinine, whereas the HCoV group reported an increase in the level of alkaline phosphatase. All groups experienced high levels of fibrinogen. In complete blood cell counts, the levels of hemoglobin ( $13•18 \pm 2•12$  vs  $10•87 \pm 2•47$ ,  $p < 0•001$ ), hematocrit ( $39•66 \pm 5•59$  vs  $33•03 \pm 7•24$ ,  $p < 0•001$ ), and red blood cell count ( $4•54 \pm 0•73$  vs  $3•58 \pm 0•85$ ,  $p < 0•001$ ) were

significantly higher in the MERS group, whereas lymphocyte count ( $38.90 \pm 27.00$  vs  $18.44 \pm 17.10$ ,  $p < 0.001$ ), red blood cell count ( $3.80 \pm 0.75$  vs  $3.58 \pm 0.85$ ,  $p < 0.05$ ), eosinophil count ( $4.38 \pm 6.09$  vs  $1.37 \pm 2.61$ ,  $p < 0.01$ ) were significantly higher in the HCoV group. Within the kidney function, blood urea nitrogen level was significantly higher in COVID-19 group than the MERS group and SARS group ( $23.38 \pm 20.07$  vs  $15.78 \pm 13.80$ ,  $p < 0.01$  and  $23.38 \pm 20.07$  vs  $12.90 \pm 11.77$ ,  $p < 0.001$ , respectively) and a significantly higher level of creatinine than the HCoV group ( $1.33 \pm 1.77$  vs  $0.58 \pm 0.64$ ,  $p < 0.01$ ). eGFR was significantly higher in the MERS and SARS groups compared to the COVID-19 group ( $105.50 \pm 61.10$  vs  $78.27 \pm 40.62$ ,  $p < 0.001$  and  $107.50 \pm 48.12$  vs  $78.27 \pm 40.62$ ,  $p < 0.05$ , respectively).

Prognostic factors(unit)	COVID-19 (n=2840)	MERS-CoV (n=67)	p-val	SARS-CoV-1 (n=43)	p-val	HCoV (n=87)	p-val
<b>Complete blood count</b>							
Hb (g/dL)	10.87 (2.47)	13.18 (2.12)	<0.0001	10.81 (2.92)	0.998	11.07 (2.19)	0.911
Hct (%)	33.03 (7.24)	39.66 (5.59)	<0.0001	31.50 (8.37)	0.650	32.45 (6.56)	0.846
Lymphocyte (%)	18.44 (17.1)	18.93 (11.75)	0.993	19.30 (15.10)	0.984	38.90 (27.00)	<0.0001
RBC (10 <sup>6</sup> /μL)	3.58 (0.85)	4.54 (0.73)	<0.0001	3.46 (0.99)	0.872	3.80 (0.75)	0.037
WBC (10 <sup>3</sup> /μL)	10.12 (15.21)	8.10 (4.11)	0.839	9.19 (6.94)	0.984	5.64 (6.02)	0.055
Eosinophil (%)	1.37 (2.61)	1.20 (1.32)	0.849	2.13 (4.71)	0.761	4.38 (6.09)	0.0020
PCT (%)	0.20 (0.11)	0.20 (0.09)	1.000	0.17 (0.09)	0.142	0.19 (0.14)	0.825
PLT (10 <sup>3</sup> /μL)	192.36 (120.45)	217.00 (100.12)	0.377	176.45 (114.49)	0.819	178.95 (152.55)	0.850
<b>Liver function</b>							
Albumin (g/dL)	3.53 (0.74)	4.17 (0.52)	<0.0001	2.94 (0.52)	<0.0001	3.76 (0.58)	0.063
Alkaline phosphatase (U/L)	152.34 (191.25)	89.98 (56.58)	0.201	111.64 (76.22)	0.460	132.41 (88.79)	0.921
Bilirubin, total (mg/dL)	1.39 (2.35)	0.67 (0.33)	<0.0001	2.37 (5.65)	0.742	0.66 (0.46)	<0.0001
AST (U/L)	85.58 (440.14)	33.50 (34.94)	0.896	108.21 (261.10)	0.993	38.40 (29.90)	0.889
ALT (U/L)	54.25 (163.63)	27.70 (24.84)	0.772	92.82 (169.53)	0.588	34.00 (31.26)	0.841
<b>Kidney function</b>							
BUN (mg/dL)	23.38 (20.07)	15.80 (13.78)	0.0044	28.50 (36.30)	0.794	12.90 (11.77)	<0.0001
Creatinine (mg/dL)	1.33 (1.77)	1.07 (1.12)	0.801	1.03 (0.94)	0.999	0.58 (0.64)	0.0090
eGFR	78.27 (40.62)	105.50 (61.10)	0.0039	107.50 (48.12)	0.023	70.79 (36.94)	0.927
<b>Coagulation function</b>							
aPTT (sec)	31.14 (12.68)	31.85 (4.65)	0.996	33.70 (7.58)	0.883	31.18 (2.86)	1.000
Fibrinogen (mg/dL)	400.28 (134.49)	454.00 (122.64)	0.391	458.81 (152.01)	0.391	407.70 (132.59)	0.999
PT(sec)	15.16 (10.50)	13.00 (1.94)	0.837	13.10 (2.69)	0.881	12.74 (0.89)	0.885

Table 2. Summary of laboratory findings between the disease groups. Data are presented as the mean  $\pm$  standard deviation for the continuous variables, otherwise the number of patients and percentage. Hb: Hemoglobin, Hct: Hematocrit, RBC: Red blood cell, WBC: White blood cell, PLT: Platelet, PCT: Procalcitonin, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, BUN: Blood urea nitrogen, eGFR: Estimated glomerular filtration rate, aPTT: Partial thromboplastin time, PT: Prothrombin time

We performed an additional association analysis between the ABO blood type and coronavirus infections. As shown in Table 3, there were no statistically significant differences between the COVID-19, SARS, and HCoV groups by blood types.

### ABO blood type comparisons

Characteristic	COVID-19 (n=2840)	MERS-CoV (n=67)	p-val	SARS-CoV-1 (n=43)	p-val	HCoV (n=87)	p-val
<b>Blood type</b>							
A	596 (20.99)	1 (1.49)	<0.0001	14 (32.56)	0.065	18 (20.69)	0.947
B	441 (15.53)	2 (2.99)	0.0028	10 (23.26)	0.166	17 (19.54)	0.310
AB	194 (6.83)	0 (0.00)	NA	2 (4.65)	0.766	5 (5.75)	0.692
O	470 (16.55)	4 (5.97)	0.018	7 (16.28)	0.962	11 (12.6)	0.333

Table 3. Summary of ABO blood type counts in each disease group

## II. Comparative analyses of the COVID-19 severity

### Demographic and clinical characteristics

After dividing the COVID-19 patients by the WHO disease severity criteria<sup>9</sup>, as demonstrated in Figure 1, 2596 people belonged to the mild group (91.4%) and 244 (8.6%) belonged to the non-mild group.




Figure 1. Flowchart of establishing cohorts by WHO guideline<sup>9</sup>

In Table 4, the mean age of mild group was  $47.9 \pm 25.7$  and 1298 (50.0%) were males, and the mean age of non-mild group was  $66.7 \pm 22.6$  and 159 (65.2%) were males. There were total 1376 COVID-19 patients with the comorbidities, of which 1240 and 136 patients belonged to the mild and non-mild group, respectively. By comparison, non-mild COVID-19 group presented significantly more comorbidities upon their hospital visits (55.7% vs. 47.8%,  $p < 0.05$ ), including cardiovascular disease (13.1% vs. 7.0%,  $p < 0.001$ ), cerebrovascular disease (4.9% vs. 2.3%,  $p < 0.05$ ), and renal disease (16.4% vs. 5.5%,  $p < 0.01$ ). For symptoms, non-mild group had significantly higher proportion of individuals reporting dyspnea (19.3% vs. 3.1%,  $p < 0.001$ ), chest pain (5.7% vs. 1.9%,  $p < 0.001$ ), and upper respiratory infections (2.5% vs. 0.7%,  $p < 0.001$ ).

Characteristic	COVID-19 (n=2840)	Mild (n=2596)	Non-mild (n=244)	p-val
<b>Gender</b>				
Male	1457 (51•30)	1298 (50•00)	159 (65•16)	<0•0001
<b>Age (years)</b>				
Total	49•48 ± 25•94	47•86 ± 25•65	66•75 ± 22•55	<0•0001
0-19	434 (15•28)	415 (15•99)	19 (7•79)	0•00067
20-39	563 (19•82)	555 (21•37)	8 (3•28)	<0•0001
40-59	561 (19•75)	536 (20•65)	25 (10•25)	<0•0001
60-79	941 (33•13)	828 (31•90)	113 (46•31)	<0•001
80+	341 (12•00)	262 (10•09)	79 (32•38)	<0•0001
<b>Comorbidities</b>				
Total	1376 (48•45)	1240 (47•77)	136 (55•74)	0•017
Diabetes	124 (4•36)	115 (4•43)	9 (3•69)	0•588
Cardiovascular disease	214 (7•53)	182 (7•01)	32 (13•11)	0•00055
Cerebrovascular disease	73 (2•57)	61 (2•35)	12 (4•92)	0•015
Malignancy	837 (29•47)	758 (29•20)	79 (32•38)	0•298
Hepatic disease	132 (4•65)	130 (5•07)	2 (0•82)	0•0012
Gastrointestinal disease	410 (14•44)	390 (15•02)	20 (8•20)	0•004
Renal disease	183 (6•44)	143 (5•51)	40 (16•39)	<0•0001
Thyroidal disease	30 (1•06)	30 (1•16)	0 (0•0)	NA
Musculoskeletal disease	63 (2•22)	55 (2•12)	8 (3•28)	0•239
<b>Symptoms</b>				
Total	1333 (46•94)	1234 (47•53)	99 (40•57)	0•037
Fever	939 (33•06)	895 (34•48)	44 (18•03)	<0•0001
Cough	102 (3•59)	97 (3•74)	5 (2•05)	0•176
Dyspnea	128 (4•51)	81 (3•12)	47 (19•26)	<0•0001
Chest pain	63 (2•22)	49 (1•89)	14 (5•74)	<0•0001
Sore throat	51 (1•80)	51 (1•96)	0 (0•0)	NA
Gastrointestinal symptoms	193 (6•80)	185 (7•13)	8 (3•28)	0•022
Upper respiratory infection	23 (0•81)	17 (0•65)	6 (2•46)	0•0026

Table 4. Summary of clinical characteristics between the COVID-19 severity groups. Data are presented as the mean ± standard deviation for the continuous variables, otherwise the number of patients and percentage

When comparing the mild and non-mild groups of COVID-19 patients, the Table 5 shows significant difference between the severity by the blood type A. From the analysis, we observed that the COVID-19 patients with blood type A were more significantly likely to progress towards the non-mild group (30•7 % vs• 20•1%,  $p < 0•001$ ).

#### ABO blood type comparisons

Characteristic	COVID-19 (n=2840)	Mild (n=2596)	Non-mild (n=244)	p-val
<b>Blood type</b>				
A	596 (20•99)	521 (20•07)	75 (30•74)	<0•0001
B	441 (15•53)	409 (15•76)	32 (13•11)	0•276
AB	194 (6•83)	172 (6•63)	22 (9•02)	0•157
O	470 (16•55)	428 (16•49)	42 (17•21)	0•770

Table 5. Summary of ABO blood type counts in each severity group

## Laboratory findings

Laboratory findings of each severity group are summarized in Table 6. From the table, we observed an increase in the count of white blood cell and the levels of blood nitrogen urea and fibrinogen within the non-mild group and an increase in the level of alkaline phosphatase within the mild group. Both severity groups reported elevated levels of aminotransferases and creatinine. Compared to the mild group, non-mild group showed statistically higher levels of white blood cell count ( $11.13 \pm 9.44$  vs  $9.99 \pm 0.16$ ,  $p < 0.05$ ), eosinophil count ( $1.93 \pm 4.30$  vs  $1.28 \pm 2.25$ ,  $p < 0.01$ ), procalcitonin ( $0.21 \pm 0.11$  vs  $0.20 \pm 0.11$ ,  $p < 0.01$ ), and platelet ( $208.26 \pm 120.78$  vs  $190.18 \pm 120.26$ ,  $p < 0.0$ ). While in liver function measurements, the mild group showed higher levels of albumin ( $3.56 \pm 0.74$  vs  $3.30 \pm 0.64$ ,  $p < 0.001$ ), alkaline phosphatase ( $156.52 \pm 200.38$  vs  $123.94 \pm 106.64$ ,  $p < 0.001$ ), and total bilirubin ( $1.45 \pm 2.47$  vs  $0.94 \pm 1.16$ ,  $p < 0.001$ ), they had lower levels of blood nitrogen urea ( $22.50 \pm 19.56$  vs  $29.56 \pm 22.45$ ,  $p < 0.001$ ), creatinine ( $1.28 \pm 1.71$  vs  $1.78 \pm 2.18$ ,  $p < 0.001$ ), and fibrinogen ( $392.81 \pm 135.42$  vs  $449.46 \pm 117.01$ ,  $p < 0.001$ ) compared to the non-mild group.

Prognostic factors(unit)	Total	Mild	Non-mild	p-val
<b>Complete blood count</b>				
Hb (g/dL)	10.97 (2.47)	10.91 (2.47)	10.58 (2.40)	0.013
Hct (%)	33.03 (7.24)	33.10 (7.25)	32.58 (7.19)	0.181
Lymphocyte (%)	18.44 (17.1)	18.63 (0.17)	17.16(16.44)	0.109
RBC (10 <sup>6</sup> /μL)	3.58 (0.85)	3.59 (0.85)	3.47 (0.82)	0.0061
WBC (10 <sup>3</sup> /μL)	10.12 (15.21)	9.99 (0.16)	11.13(9.44)	0.043
Eosinophil (%)	1.37 (2.61)	1.28 (2.25)	1.93 (4.30)	0.0090
PCT (%)	0.20 (0.11)	0.20 (0.11)	0.21 (0.11)	0.0027
PLT (10 <sup>3</sup> /μL)	192.36 (120.45)	190.18 (120.26)	208.26 (120.78)	0.0057
<b>Liver function</b>				
Albumin (g/dL)	3.53 (0.74)	3.56 (0.74)	3.30 (0.64)	<0.0001
Alkaline phosphatase (U/L)	152.34 (191.25)	156.52 (200.38)	123.94 (106.64)	<0.0001
Bilirubin, total (mg/dL)	1.39 (2.35)	1.45 (2.47)	0.94(1.16)	<0.0001
AST (U/L)	85.58 (440.14)	88.08(456.98)	67.99 (295.15)	0.274
ALT (U/L)	54.25 (163.63)	53.57(143.78)	59.05 (2644.81)	0.705
<b>Kidney function</b>				
BUN (mg/dL)	23.38 (20.07)	22.50 (19.56)	29.56 (22.45)	<0.0001
Creatinine (mg/dL)	1.33 (1.77)	1.28(1.71)	1.78 (2.18)	<0.0001
eGFR	78.27 (40.62)	79.41(39.98)	70.66 (43.97)	0.00041
<b>Coagulation function</b>				
aPTT (sec)	31.14 (12.68)	31.12(12.46)	31.22 (14.06)	0.909
Fibrinogen (mg/dL)	400.28 (134.49)	392.81(135.42)	449.46 (117.01)	<0.0001
PT (sec)	15.16 (10.50)	15.15(11.11)	15.25 (4.79)	0.801

Table 6. Summary of laboratory findings between the COVID severity groups. Data are presented as the mean  $\pm$  standard deviation for the continuous variables, otherwise the number of patients and percentage. Hb: Hemoglobin, Hct: Hematocrit, RBC: Red blood cell, WBC: White blood cell, PLT: Platelet, PCT: Procalcitonin, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, BUN: Blood urea nitrogen, eGFR: Estimated glomerular filtration rate, aPTT: Partial thromboplastin time, PT: Prothrombin time

### III. Logistic regression

In order to observe the extent of common clinical characteristics among disease groups that may uniquely affect the prognosis of COVID-19 patients, we conducted a nominal logistic regression with the variables that showed the p values higher than 0.05 in two thirds of the comparative groups between the diseases and less than 0.05 in the analyses between the disease severity groups. We found no collinearity between the variables. Table 7 below shows the results from regression that has been adjusted for both age and gender. The univariate logistic regression showed that the male patients (OR: 1.66; CI: 1.29-2.13,  $p < 0.001$ ) with ABO blood type A (OR: 1.80; CI: 1.40-2.31,  $p < 0.001$ ), renal disease (OR: 3.27; CI: 2.34-4.55,  $p < 0.001$ ), decreased creatinine (OR: 2.05; CI: 1.45-2.88,  $p < 0.001$ ), and increased level of fibrinogen (OR: 1.59, CI: 1.21-2.09,  $p < 0.001$ ) are associated with the higher risks of progressing towards the more severe stage whereas the patients with gastrointestinal symptoms (OR: 0.42; CI: 0.23-0.72,  $p < 0.01$ ) and increased alkaline phosphatase (OR: 0.73; CI: 0.56-0.94,  $p < 0.05$ ) are less likely to experience the severe prognosis of the disease. Age was not associated with risk of high severity.

Prognostic factors	OR (95% CI)	p-value
<b>Age (years)</b>	1.04 (1.02, 1.06)	0.00087
0-19	2.74 (0.46, 16.04)	0.265
20-39	1.18 (0.30, 4.53)	0.808
40-59	0.82 (0.36, 1.85)	0.636
60-79	0.80 (0.52, 1.23)	0.311
<b>Male, Sex</b>	1.66 (1.29, 2.13)	<0.0001
<b>Blood type (A)</b>	1.80 (1.40, 2.31)	<0.0001
<b>Dyspnea</b>	5.36 (3.88, 7.41)	<0.0001
<b>Renal disease</b>	3.27 (2.34, 4.55)	<0.0001
<b>Gastrointestinal symptoms</b>	0.42 (0.23, 0.72)	0.0032
<b>Hb (g/dL)</b>		
High	2.17 (0.94, 4.70)	0.057
Low	0.98 (0.73, 1.32)	0.882
<b>WBC (<math>10^3/\mu\text{L}</math>)</b>		
High	1.38 (1.06, 1.80)	0.016
Low	1.72 (1.18, 2.49)	0.0044
<b>Eosinophil (%)</b>		
High	1.50 (0.76, 2.80)	0.217
Low	0.94 (0.74, 1.20)	0.628
<b>PCT (%)</b>		
High	0.88 (0.40, 1.98)	0.753
Low	0.73 (0.54, 0.99)	0.045
<b>PLT (<math>10^3/\mu\text{L}</math>)</b>		
High	2.25 (1.05, 4.60)	0.030
Low	0.97 (0.68, 1.37)	0.845
<b>Alkaline Phosphatase (U/L)</b>		
High	0.73 (0.56, 0.94)	0.015
Low	0.36 (0.06, 1.30)	0.182
<b>Creatinine (mg/dL)</b>		

High	0.92 (0.68, 1.23)	0.575
Low	2.05 (1.45, 2.88)	<0.0001
<b>Fibrinogen (mg/dL)</b>		
High	1.59 (1.21, 2.09)	0.00084
Low	0.81 (0.36, 1.63)	0.574

Table 7. Nominal logistic regression adjusted for age and gender. Hb: Hemoglobin, WBC: White blood cell, PCT: Procalcitonin, PLT: Platelet. Normal ranges served as the reference values for all measurement variables




Figure 2. Proportion of prognostic factors in non-mild COVID-19 patients




Figure 3. Proportion of prognostic factors in disease groups

Figure 2 shows the proportion of patients with risk factors in non-mild group, of which elevated fibrinogen level (72.5%) and male sex (58.2%) most commonly appeared. When comparing the identical parameters in different disease groups, Figure 3 shows that the proportions of patients in male sex (72.1%), blood type A (32.6%), dyspnea, and renal disease were the highest in SARS group whereas the number of patients with elevated WBC was the highest in MERS group. The rates of elevated fibrinogen were similar in SARS and MERS groups with 25% and 26.2%, respectively.

## Discussion

The present retrospective cohort study examined the clinical resemblance between the coronavirus infected patients within South Korea and identified the common characteristics and risk factors that can potentially influence a severity of the novel COVID-19. In our findings, we discovered the most similarities in clinical features between the COVID-19 group, especially the non-mild COVID-19 patients, and SARS group, showing statistical similarities that range from 75-89.5% in their manifestations. Our observation between the SARS-CoV-2 and SARS-CoV-1, analogous to a previous study by Petrosillo et al<sup>16</sup>, maybe attributed to a resemblance of 70-80% in genomic sequences. It is also to note that the two viruses utilize an angiotensin-converting enzyme 2 (ACE2) receptor across multiple species, suggesting the common cellular binding mechanism as the basis of parallel pathogeneses in COVID-19 and SARS patients<sup>17</sup>.

Another important finding was that the male sex, blood type A, renal disease, and elevated level of fibrinogen were major risk factors in virus infections and severe prognosis of COVID-19. In line with our observation in the patient demographics, of which more than 50% of individuals were males, previous research on SARS data in Hong Kong showed enhanced fatality rate in men by 21.9% compared to women with 13.2%<sup>18</sup> whereas the South Korean and Saudi Arabic MERS-CoV data predominantly reflected male sex in infected population, with the respective frequencies of 65.2% and 59.1%<sup>19</sup>. One theory for a higher risk in males includes greater circulating ACE2 levels than in women, which creates a sex-dependent difference in virus infection<sup>17,20</sup>, evidenced by a positive correlation of susceptibility of male mice to SARS-CoV and virus titers observed in a vitro study<sup>21</sup>. However, sex-dependent discrepancy is multifactorial, which would also require further investigations in relation to socioeconomic and behavioral elements.

In our study, we did not see a significant difference within a distribution of ABO blood types between the disease groups, yet the proportion of blood type A individual was significantly higher in the non-mild COVID-19 group. Such finding parallels to the meta-analysis on Spanish and Italian patient data where the odds for having severe COVID-19 were higher in A/AB groups as compared with B/O group<sup>22</sup>. Similarly, the Hong Kong study on SARS outbreak reported higher susceptibility to the infection in blood type A group<sup>23</sup>. While the research regarding the association between ABO blood type and coronavirus infection is relatively new, one potential mechanism of type A group's susceptibility can be attributed to a strong affinity of SARS-CoV-2 spike protein to the carbohydrates, such as galactose in the A antigen, unlike a galactose amine that is present as end group saccharide in the B and O antigens<sup>24</sup>. Another speculation pertaining to severity risk difference between the type A and non-A patients involves a protective role of neutralizing anti-A antibody blocking the interaction of ACE2 and S protein<sup>25</sup>.

The kidney failures were evident in all disease groups and were shown to be the variable with the second-highest risk rate next to dyspnea. Firstly, ACE2, which is present in multiple organs has also been found to be highly expressed on renal cells, facilitating SARS-CoV-2 entry and consequent acute tubular injury, and occasionally collapsing focal segmental glomerulopathy in the kidney tissue. Studies suggest a decrease in the ACE2 as a result of viral attachment to the receptor and the consequent elevation in the level of AngII and AT1R I stimulation, which induce an aggravation of respiratory distress in COVID-19 patients<sup>26-27</sup>. Further, CKD patients are predisposed to the poorer outcomes—their immunosuppressed state and chronic systemic inflammation can increase the risks of developing more severe

complications and mortality<sup>28</sup>. Likewise, in our data, chronic kidney disease (CKD) and acute kidney injury (AKI) were the two most frequently reported diagnoses.

Of the major laboratory findings, we noticed the overall increase fibrinogen in our cohorts, especially within the non-mild COVID-19 group. Elevated fibrinogen level can be an indicator for hypercoagulability due to viral pneumonia<sup>29</sup>, which is a common complication in coronavirus infections. A literature review by Abou-Ismaïl et al revealed the prothrombotic traits in SARS-CoV-2 patients globally, which is also evidenced by our records that showed occurrences of thrombotic manifestation including pulmonary embolism, myocardial infarction, ischemic stroke, and deep vein thrombosis (DVT) in COVID-19 and SARS patients. Coagulopathy in coronavirus infected patients has been linked to a heightened inflammatory response that typically leads to thrombo-inflammation. The inflammation is suspected to begin in lungs damaging the pulmonary vasculature that leads to thrombosis in the early stage of the disease<sup>30</sup>.

To conclude, our study detected the highest resemblance between the COVID-19 and SARS groups. Further, clinical manifestations that were present in SARS group were linked to the severity of COVID-19. The regression model, upon applying the common variables between the disease groups, indicated male sex, blood type A, dyspnea, renal disease, and elevated levels of white blood cell, platelet, fibrinogen and alkaline phosphatase, and decreased creatinine level as the risk factors of severe COVID-19. Our study had several limitations; first, there existed missing data, which may explain a disparity in our creatinine analyses. Considering the relative nature of logistic regression, we speculate the model to presume the contradictory correlations between the disease severity and creatinine level—only 16% of the individuals with high creatinine level belonged to the non-mild group, yet it should be noted that the number of admitted severe patients in Seoul National University Hospital was relatively low. Second, the study population was limited to the patients at a single national hospital. Thus, the results in this study should not be generalized fully to other populations and ought to be considered with a caution.

Yet, we maximized the benefit of utilizing the anonymized EMR data integrated into CDM, which now is expanding in its scope globally for the vitalization of medical research. With the frequent data imports, we were able to reflect the real-world medical challenges in managing coronavirus infection, providing the most updated clinical dynamics. To our knowledge, this is the first study that attempts to clinically characterize and compare four major human coronavirus infections as well as to identify the common risk factors found in previous viral infections that may influence the prognosis of novel COVID-19. With our analyses that applied the variables of both the statistical and clinical significance, we expect the results from the present study to provide clinical insights that can be used as a basis for predicting the prospective clinical representations by yet another coronavirus-derived illness in near future and to serve the guidelines for clinical treatments of current patients. However, there still left a great uncertainty around the set of symptoms and complications from coronavirus, and it is absolutely crucial to further investigate for attaining a better understanding of the disease. For future study, therefore, we recommend performing a cross-country clinical characterization and survival analysis to determine risk factors that are particular to ethnic group, which shall aid in developing more specific control and prevention schemes for each country. Moreover, it will be insightful to analyze the manifestations at a multidimensional perspective, including the patients' socioeconomic background, nutritional status, and behavioral habit that might exert an influence on the disease outcomes.

## Acknowledgement

This work was supported by the Technology Innovation Program (20003883, Technology development on CDM-based biohealth integrated data network extension) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI19C1234). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

## References

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: <https://covid19.who.int/> [Accessed on October 15<sup>th</sup>, 2020]
2. Chaw SM, Tai JH, Chen SL, et al. The origin and underlying driving forces of the SARS-CoV-2 outbreak. *Journal of Biomedical Science*. 2020; 27(73). Available from: [doi.org/10.1186/s12929-020-00665-8](https://doi.org/10.1186/s12929-020-00665-8) [Accessed on October 20<sup>th</sup>, 2020]
3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nature reviews Microbiology*. 2019; 17(3), 181-192. Available from: [doi.org/10.1038/s41579-018-0118-9](https://doi.org/10.1038/s41579-018-0118-9) [Accessed on October 20<sup>th</sup>, 2020]
4. Zhu Z, Lian X, Su X, et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. *Respiratory Research*. 2020; 21, 224. Available from: [doi.org/10.1186/s12931-020-01479-w](https://doi.org/10.1186/s12931-020-01479-w) [Accessed on September 18<sup>th</sup>, 2020]
5. Izcovich A, Ragusa MA, Tortosa FT, Marzio MAL, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. *PLoS ONE*. 2020; 15(11): e0241955. Available from: [doi.org/10.1371/journal.pone.0241955](https://doi.org/10.1371/journal.pone.0241955) [Accessed on November 20<sup>th</sup>, 2020]
6. Krishnamoorthy S, Swain B, Verma RS, Gunthe SS. (2020) SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations. *VirusDisease*. 2020; 31: 411–423. Available from: [doi.org/10.1007/s13337-020-00632-9](https://doi.org/10.1007/s13337-020-00632-9) [Accessed on October 20<sup>th</sup>, 2020]
7. OHDSI (Observational Health Data Sciences and Informatics). OMOP Common Data Model. Available from: <https://www.ohdsi.org/data-standardization/the-common-data-model/> [Accessed on October 20<sup>th</sup>, 2020]
8. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD)-10 version:2019. Available from: <https://icd.who.int/browse10/2019/en> [Accessed on August 3<sup>rd</sup>, 2020]
9. World Health Organization. Clinical Management of COVID-19. Available from: <https://www.who.int/publications/i/item/clinical-management-of-covid-19> [Accessed on August 20<sup>th</sup>, 2020]
10. Seoul Clinical Laboratories. 2020 SCL Test information (검사안내). Yongin-si, South Korea: Seoul Clinical Laboratories; 2020.
11. Brady SM, Burow M, Busch W, et al. Reassess the t Test: Interact with All Your Data via ANOVA. *Plant Cell*. 2015 27(8):2088-2094. Available from: [doi:10.1105/tpc.15.00238](https://doi.org/10.1105/tpc.15.00238) [Accessed on September 1<sup>st</sup>, 2020]
12. Mishra P, Singh U, Pandey CM, Mishra P, Pandey G. Application of student's *t*-test, analysis of variance, and covariance. *Annals of Cardiac Anaesthesia*. 2019; 22(4):407-411. Available from: [doi:10.4103/aca.ACA\\_94\\_19](https://doi.org/10.4103/aca.ACA_94_19) [Accessed on September 1<sup>st</sup>, 2020]


13. Kim HY. Statistical notes for clinical researchers: Chi-squared test and Fisher's exact test. *Restorative Dentistry Endodontics*. 2017;42(2):152-155. Available from: doi:10.5395/rde.2017.42.2.152 [Accessed on September 2<sup>nd</sup>, 2020]
14. Sperandei S. Understanding logistic regression analysis. *Biochemia Medica (Zagreb)*. 2014;24(1):12-18. Available from: doi:10.11613/BM.2014.003 [Accessed on September 2<sup>nd</sup>, 2020]
15. Xu K, Zhou M, Yang D, et al. Application of ordinal logistic regression analysis to identify the determinants of illness severity of COVID-19 in China. *Epidemiology and Infection*. 2020;148:e146. Available from: doi:10.1017/S0950268820001533 [Accessed on October 1<sup>st</sup>, 2020]
16. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? *Clinical Microbiology and Infection*. 2020; 26(6), 729-734. Available from: doi.org/10.1016/j.cmi.2020.03.026 [Accessed on August 1<sup>st</sup>, 2020]
17. Khan MI, Khan ZA, Baig MH, Farouk A-EAziem, Song YG, et al. Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight. *PLoS ONE*. 2020;15(9): e0238344 Available from: doi.org/10.1371/journal.pone.0238344 [Accessed on September 17<sup>th</sup>, 2020]
18. Agrawal H, Das N, Nathani S, et al. An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner. *Stem Cell Reviews and Reports*. 2020. Available from: doi.org/10.1007/s12015-020-10048-z [Accessed on October 15<sup>th</sup>, 2020]
19. Chen X, Chughtai AA, Dyda A, MacIntyre CR. Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. *Emerging Microbes & Infection*. 2017;6(6):e51. Available from: doi:10.1038/emi.2017.40 [Accessed on August 27<sup>th</sup>, 2020]
20. Bwire GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? *SN Comprehensive Clinical Medicine*. 2020;1-3. Available from: doi:10.1007/s42399-020-00341-w [Accessed on November 1<sup>st</sup>, 2020]
21. Channappanavar R, Fett C, Mack M, Eyck PPT, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection/ *The Journal of Immunology*. 2017; 198 (10) 4046-4053. Available from: doi: 10.4049/jimmunol.1601896 [Accessed on November 16<sup>th</sup>, 2020]
22. Bhattacharjee S, Banerjee M, Pal RABO blood groups and severe outcomes in COVID-19: A meta-analysis. *Postgraduate Medical Journal*. 2020. Available from: doi: 10.1136/postgradmedj-2020-139248 [Accessed on November 15<sup>th</sup>, 2020]
23. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK, Ng MH, Sung JJ, Wong RS. ABO blood group and susceptibility to severe acute respiratory syndrome. *JAMA*. 2005;

- 23;293(12):1450-1. Available from: doi: 10.1001/jama.293.12.1450-c. [Accessed on November 1<sup>st</sup>, 2020]
24. Hultström M, Persson B, Eriksson O, et al. Blood type A associates with critical COVID-19 and death in a Swedish cohort. *Critical Care*. 2020; 24, 496. Available from: doi.org/10.1186/s13054-020-03223-8 [Accessed on October 31<sup>st</sup>, 2020]
25. Guillon P, Clément M, Sébille V, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. *Glycobiology*. 2008;18(12):1085-1093. Available from: doi:10.1093/glycob/cwn093 [Accessed on November 4<sup>th</sup>, 2020]
26. Lin L, Wang X, Ren J, et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. *BMJ Open*. 2020;10:e042573. Available from: doi: 10.1136/bmjopen-2020-042573 [Accessed on November 12<sup>th</sup>, 2020]
27. Battle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. *Journal of the American Society of Nephrology*. 2020; (7):1380-1383. Available from: doi: 10.1681/ASN.2020040419 [Accessed on November 1<sup>st</sup>, 2020]
28. D'Marco L, Puchades MJ, Romero-Parra M, et al. Coronavirus disease 2019 in chronic kidney disease. *Clinical Kidney Journal*. 2020;13(3):297-306. Available from: doi:10.1093/ckj/sfaa104 [Accessed on November 5<sup>th</sup>, 2020]
29. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. *Pathobiology*. 2020. Available from: doi.org/10.1159/000512007 [Accessed on November 3<sup>rd</sup>, 2020]
30. Abou-Ismaïl MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thrombosis Research*. 2020;194:101-115. Available from: doi:10.1016/j.thromres.2020.06.029 [Accessed on November 27<sup>th</sup>, 2020]

## Appendix 1. Normal Range


	Normal Range		Unit
	Pediatrics	Adults	
<b>Albumin</b>	3•5-5•2		g/dL
<b>Alkaline phosphatase</b>	M: 40-130 F: 35-105		U/L
<b>Bilirubin, total</b>	<1•2		mg/dL
<b>GOT (AST)</b>	M: <40 F: <33		U/L
<b>GPT (ALT)</b>	M: <41 F: <33		U/L
<b>Hb</b>	1-2 months	M: 10•2-12•7 F: 11•1-13•7	M: 13-17 F: 12-16 g/dL
	2-6 months	M: 10•5-13•0 F: 10•7-13•4	
	6 months – 2 yrs	M: 10•4-12•5 F: 10•8-12•6	
	2 yrs – 6 yrs	M: 11•0-12•8 F: 11•1-12•9	
	6 rs – 12 yrs	M: 11•0-13•3 F: 11•3-13•4	
	12 yrs – 18 yrs	M: 11•0-14•3 F: 11•3-13•4	
<b>Hct</b>	1-2 months	M: 29•1-36•6 F: 32•0-39•9	M: 39-52 F: 36-48 %
	2-6 months	M: 30•5-37•7 F: 30•5-38•6	
	6 months – 2 yrs	M: 30•5-36•4 F: 30•9-36•4	
	2 yrs – 6 yrs	M: 31•5-36•8 F: 31•8-37•0	
	6 rs – 12 yrs	M: 31•5-38•0 F: 32•3-38•3	
	12 yrs – 18 yrs	M: 31•4-41•0 F: 32•1-38•7	
<b>Lymphocyte</b>	1-2 months	M: 12•0-68•0 F: 16•0-68•0	17•0-46•0 %
	2-6 months	M: 16•0-68•0 F: 15•0-68•0	
	6 months – 2 yrs	M: 15•0-67•0 F: 13•0-70•0	
	2 yrs – 6 yrs	M: 11•0-54•0 F: 11•0-59•0	
	6 rs – 12 yrs	M: 8•0-45•0 F: 10•0-47•0	
	12 yrs – 18 yrs	M: 8•0-41•0 F: 8•0-39•0	
<b>RBC</b>	1-2 months	M: 3•24-4•08 F: 3•55-4•57	M: 4•2-6•3 F: 4•0-5•4 *10 <sup>6</sup> /μL
	2-6 months	M: 3•67-4•61 F: 3•63-4•61	
	6 months – 2 yrs	M: 3•81-4•74 F: 3•83-4•67	
	2 yrs – 6 yrs	M: 3•92-4•72 F: 3•83-4•67	

	6 rs – 12 yrs	M: 3•85-4•75 F: 3•88-4•72		
	12 yrs – 18 yrs	M: 3•74-4•93 F: 3•79-4•61		
<b>WBC</b>	1-2 months	M: 8•36-13•66 F: 7•34-12•31	4-10	*10 <sup>3</sup> /μL
	2-6 months	M: 7•91-13•41 F: 6•85-12•84		
	6 months – 2 yrs	M: 7•73-13•12 F: 7•05-12•98		
	2 yrs – 6 yrs	M: 5•97-10•49 F: 5•98-10•08		
	6 rs – 12 yrs	M: 5•69-9•88 F: 5•41-9•70		
	12 yrs – 18 yrs	M: 5•24-9•74 F: 35•52-9•29		
<b>Eosinophil</b>	1-2 months	M: 2•0-5•0 F: 2•0-6•0	1-6	%
	2-6 months	M: 2•0-6•0 F: 2•0-5•0		
	6 months – 2 yrs	M: 1•0-5•0 F: 1•0-4•0		
	2 yrs – 6 yrs	M: 1•0-4•0 F: 1•0-4•0		
	6 rs – 12 yrs	M: 2•0-4•0 F: 1•0-4•0		
	12 yrs – 18 yrs	M: 2•0-4•0 F: 1•0-3•0		
<b>PCT</b>		M: 0•19-0•39 F: 0•19-0•41		%
<b>PLT</b>	1-2 months	M: 221-471 F: 184-430	130-400	*10 <sup>3</sup> /μL
	2-6 months	M: 215-448 F: 147-423		
	6 months – 2 yrs	M: 185-399 F: 211-408		
	2 yrs – 6 yrs	M: 211-370 F: 190-365		
	6 rs – 12 yrs	M: 227-350 F: 210-339		
	12 yrs – 18 yrs	M: 180-299 F: 192-307		
<b>BUN</b>	< 1y r	4-19	18-60 yrs: 6-20	mg/dL
	< 18 yrs	5-18	61-90 yrs: 8-23	
<b>Creatinine</b>		M: 0•7-1•20 F: 0•5-0•9		mg/dL
<b>eGFR</b>		> 60		
<b>CK (CPK)</b>		M: 39-308 F: 26-192		U/L
<b>aPTT</b>		28•5-45•4		sec
<b>Fibrinogen</b>		200-400		mg/dL
<b>PT</b>		11•8-15•3		sec



- A. Patients with general symptoms including cough, fatigue, dyspnea, myalgias, sore throat, nasal congestion, headache, diarrhea and vomiting
- B. Patients diagnosed with pneumonia within 7 days since the first COVID-19 positive test
- C. Adults and adolescents: SpO<sub>2</sub> ≥ 90% or RR ≥ 20 breaths/min; 2 months: RR ≥ 60 breaths/min; 2-11 months: RR ≥ 50 breaths/min; 1-5 years : RR ≥ 40 breaths/min
- D. Adults and adolescents: SpO<sub>2</sub> < 90% or RR ≥ 20 breaths/min, Pediatrics: Convulsions or unconsciousness + SpO<sub>2</sub> < 90% or RR ≥ 60 breaths/min; 2-11 months: RR ≥ 50 breaths/min; 1-5 years : RR ≥ 40 breaths/min

**Proportion of prognostic factors in non-mild COVID-19 patients**



Proportion of prognostic factors in disease groups

